Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/16187
Title: Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea
Authors: Douglas, Genevieve;Harrison, Claire;Forsyth, Cecily J;Bennett, Michael R;Stevenson, William;Hounsell, John;Ratnasingam, Sumita;Ritchie, David;Ross, David M;Grigg, Andrew P
Issue Date: Jan-2017
EDate: 2016-07-25
Citation: Leukemia & Lymphoma 2017; 58(1): 89-95
Abstract: Hydroxyurea (Hu) is widely used as first-line cytoreductive therapy for patients with high-risk Philadelphia-negative myeloproliferative neoplasms (Ph-neg MPN), but a small proportion of patients have refractory disease or experience adverse effects. Studies have demonstrated busulfan (Bu) to be an active first-line agent, but data on its role as second-line or later therapy are minimal. To evaluate its efficacy and safety in this context, we undertook a multicenter audit of Ph-neg MPN patients who had received Bu as therapy for Hu intolerance or failure. Of 51 patients identified, 38 (75%) achieved either complete or partial hematological response following at least one Bu cycle. Bu was generally well tolerated, with only 21/135 (15%) cycles complicated by adverse effects, predominantly cytopenia; only 6% of cycles were ceased due to treatment complications. Bu is an effective and well-tolerated agent in patients with Ph-neg MPN in the setting of Hu intolerance or unresponsiveness.
URI: http://ahro.austin.org.au/austinjspui/handle/1/16187
DOI: 10.1080/10428194.2016.1187269
PubMed URL: http://www.ncbi.nlm.nih.gov/pubmed/27454522
Type: Journal Article
Subjects: Philadelphia-negative myeloproliferative neoplasms
Busulfan
Hydroxyurea
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.